Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

AD1 Holdings Limited

AD1

AD1 Holdings Ltd. provides an on-line database and search platform to link employers and job candidates. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2016-06-23. The firm is focused on providing and delivering software services and technology platforms to its customers, and other related supporting and consulting services. The firm operates in two verticals: HR Services and Niche Services. Under HR services, it provides software-as-a-service (SaaS) solutions in talent recruitment, employer value propositions in the form of ApplyDirect and Jobtale and mentoring products and services under the Art of Mentoring (AoM) banner. ApplyDirect provides customer-branded recruitment marketing platforms and related digital services. AoM provides mentoring programs that empower organizations to shift culture and develop their people. The company also operates Utility Software Solutions (USS), which specializes in SaaS-hosted customer interface solutions (CIS) and business process outsourcing (BPO) services for energy providers.

Acrux Limited

ACR

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto(estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Accent Resources NL

ACS

Accent Resources NL engages in the exploration of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-08-26. The firm is engaged in the exploration and evaluation of mineral deposits. The Company’s exploration focus has been on the discovery and development of iron ore, base metal and precious metal deposits at its project areas in Western Australia. The Company’s projects include Magnetite Range Project and Norseman Project. The Magnetite Range Project is an advanced iron project with greenfield gold potential, located approximately 260 kilometers east southeast of Geraldton and immediately adjacent, to the strike of the operating Extension Hill iron ore mine. The Norseman Project comprises over five mining leases and over eight prospecting licenses covering an area of approximately 338 hectares and is located five kilometers south of Norseman in the Dundas Mineral Field. The Norseman Project area occurs within a mineralized portion of the southern Norseman-Wiluna greenstone belt of the Yilgarn Craton.